Key points are not available for this paper at this time.
In this study, crizotinib showed marked antitumor activity in patients with advanced ROS1-rearranged NSCLC. ROS1 rearrangement defines a second molecular subgroup of NSCLC for which crizotinib is highly active. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.).
Building similarity graph...
Analyzing shared references across papers
Loading...
New England Journal of Medicine
University of Chicago
Massachusetts General Hospital
Dana-Farber Cancer Institute
Add This Paper to Your Research Feed
Any time a new paper drops it will be there.
Shaw et al. (Sat,) studied this question.